ACHV ACHIEVE LIFE SCIENCES, INC.

Nasdaq achievelifesciences.com


$ 4.49 $ -0.14 (-3.05 %)    

Monday, 10-Nov-2025 16:01:45 EST
QQQ $ 623.82 $ 4.38 (0.71 %)
DIA $ 473.95 $ 1.94 (0.41 %)
SPY $ 681.69 $ 4.15 (0.61 %)
TLT $ 89.46 $ 0.06 (0.07 %)
GLD $ 380.15 $ 2.40 (0.64 %)
$ 4.45
$ 4.67
$ 4.23 x 40
$ 4.59 x 500
$ 4.39 - $ 4.67
$ 1.84 - $ 5.78
607,363
na
236.89M
$ 1.55
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-11-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-28-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-16-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-10-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 03-11-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-14-2020 03-31-2020 10-Q
24 03-13-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-15-2019 03-31-2019 10-Q
28 03-14-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 03-01-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 07-31-2017 06-30-2017 10-Q
35 05-15-2017 03-31-2017 10-Q
36 02-23-2017 12-31-2016 10-K
37 11-10-2016 09-30-2016 10-Q
38 08-04-2016 06-30-2016 10-Q
39 05-12-2016 03-31-2016 10-Q
40 03-09-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 achieve-life-sciences-announces-fda-accepted-cytisinicline-new-drug-application-to-treat-nicotine-dependence-pdufa-date-set-for-june-20-2026

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and...

 achieve-life-sciences-q3-eps-028-misses-026-estimate

Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate ...

 achieve-life-sciences-announces-key-nda-milestones-for-cytisinicline-co-submits-120-day-update-to-fda-concludes-orca-ol-safety-trial-dsmc-finds-no-safety-concerns-for-cytisinicline

Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and ...

 4-biotech-stocks-lifting-off-as-momentum-builds

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and...

 fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, a...

 achieve-life-sciences-appoints-craig-donnelly-to-coo

- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development an...

 achieve-life-sciences-inches-closer-to-fda-nod-for-first-new-quit-smoking-drug-in-20-years

HC Wainwright backs Achieve Life Sciences with a Buy rating as cytisinicline nears potential 2026 FDA approval, targeting a lar...

 hc-wainwright--co-initiates-coverage-on-achieve-life-sciences-with-buy-rating-announces-price-target-of-12

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Achieve Life Sciences (NASDAQ:ACHV) with a Buy rating a...

 achieve-life-sciences-q2-eps-037-beats-038-estimate

Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION